Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

47 ta ish

Ish: Personalized rosuvastatin therapy in problem patients with partial statin intolerance

  1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

    Colin Baigent, Anthony Keech, Patricia M. Kearney +8

    Sharh maqola20056 iqtibos
    ABI

  2. <i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

    The SEARCH Collaborative Group

    Maqola20083 iqtibos
    ABI

  3. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler +6

    Maqola20043 iqtibos
    ABI

  4. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    William E. Evans, Howard L. McLeod

    Maqola20033 iqtibos
    ABI

  5. Effect of Polymorphic <i>CYP3A5</i> Genotype on the Single‐Dose Simvastatin Pharmacokinetics in Healthy Subjects

    Kyoung‐Ah Kim, Pil‐Whan Park, Ock‐Je Lee +2

    Maqola20063 iqtibos
    ABI

  6. Comprehensive efforts to increase adherence to statin therapy

    Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen +13

    Maqola20163 iqtibos
    ABI

  7. <i>CYP3AP1*3</i>Allele Is Associated With Lipid-Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

    Yanpeng Li, Lirong Zhang, Min Jia +1

    Maqola20102 iqtibos
    ABI

  8. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

    Marilu Fiegenbaum, F DASILVEIRA, C VANDERSAND +4

    Maqola20052 iqtibos
    ABI

  9. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

    Paul Martin, Mike J. Warwick, Aaron Dane +4

    Maqola20032 iqtibos
    ABI

  10. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

    Joseph P. Kitzmiller, Jasmine A. Luzum, Damiano Baldassarre +2

    Maqola20142 iqtibos
    ABI

  11. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

    Laure Elens, Matthijs L. Becker, Vincent Haufroid +5

    Maqola20112 iqtibos
    ABI

  12. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

    Fumihiro Sata

    Maqola20002 iqtibos
    ABI

  13. Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients

    Patricia D. Maningat, Jan L. Breslow

    Maqola20112 iqtibos
    ABI

  14. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

    Daqing Wang, Yingying Guo, Steven Wrighton +2

    Maqola20102 iqtibos
    ABI

  15. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

    Sharh maqola20152 iqtibos
    ABI

  16. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen +1

    Maqola20062 iqtibos
    ABI

  17. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI